All In Biotech

BLA 022472 · Mannkind

Afrezza

Insulin Recombinant Human · Inhalation · Insulin

Last checked: Nov 20, 2026Latest source record: May 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jun 27, 2014

Approved uses

4

Original approval plus efficacy supplements

Registered trials

100

15 Phase 3, 0 recruiting

FAERS reports

8,026

5,651 serious, 789 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and Chronic Obstructive Pulmonary Disease (COPD) [see Warnings and Precautions ( 5.1 )]. AFREZZA is contraindicated in patients with chronic lung disease such as asthma or COPD [see Contraindications ( 4 )]. Before initiating AFREZZA, perform a detailed medical history, physical examination, and spirometry (FEV 1 ) to identify potential lung disease in all patients [see Dosage and Administration ( 2.1 ), Warnings and Precautions ( 5.1 )]. WARNING: RISK OF ACUTE BRONCHOSPASM IN PATIENTS WITH CHRONIC LUNG DISEASE See full prescribing information for complete boxed warning. Acute bronchospasm has been observed in AFREZZA-treated patients with asthma and Chronic Obstructive Pulmonary Disease (COPD). ( 5.1 ) AFREZZA is contraindicated in...

What it is approved for

From the label in effect May 30, 2026.

AFREZZA ® is indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus. AFREZZA ® is a rapid acting inhaled human insulin indicated to improve glycemic control in adult and pediatric patients 6 years of age and older with diabetes mellitus. ( 1 ) Limitations of Use : Not recommended for the treatment of diabetic ketoacidosis (DKA) ( 1 ) Not recommended in patients who smoke or who have recently stopped smoking ( 1 ) Limitations of Use: AFREZZA is not recommended for the treatment of diabetic ketoacidosis (DKA) [see Warnings and Precautions ( 5.6 )] . The safety and effectiveness of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking [see Warnings and Precautions ( 5.5 )].

Mechanism: Insulin lowers blood glucose levels in adult patients with diabetes mellitus by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis in adipocytes, inhibits proteolysis, and enhances protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • AFREZZA · INSULIN RECOMBINANT HUMAN 12 UNITS/INH · POWDER, INHALATION · Prescription
  • AFREZZA · INSULIN RECOMBINANT HUMAN 4 UNITS/INH · POWDER, INHALATION · Prescription
  • AFREZZA · INSULIN RECOMBINANT HUMAN 8 UNITS/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Recombinant Human" as an intervention, any sponsor and status, largest first.

All 100 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased1,327
  • drug ineffective583
  • hypoglycaemia458
  • cough446
  • blood glucose decreased398
  • dyspnoea398
  • hyperglycaemia357
  • diarrhoea341
  • off label use319
  • headache283
  • nausea271
  • wrong technique in product usage process263

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200454
200554
200644
200773
200869
200967
201076
2011100
201296
2013160
2014369
20151,116
2016315
2017201
2018512
2019448
2020400
2021581
2022791
2023701
2024681
2025647
2026471

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Afrezza (Insulin Regular, Human)

2024 spending

$26.9M

Beneficiaries

3,114

13,165 claims

Per beneficiary

$8,632

$8.98 per unit

View as table
YearSpending
2020$8,007,830
2021$10,393,693
2022$12,896,498
2023$22,608,794
2024$26,879,300

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Mannkind

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.